Type 2 diabetes patients who used dapagliflozin as an add-on to sitagliptin treatment attained a 24.9% increase in beta-cell function from baseline, compared with a 5.2% increase in the placebo group, according to a study in Diabetes Care. Researchers also found more patients in the dapagliflozin arm had HbA1C levels below 7.0% than those who took a placebo. However, dapagliflozin was tied to higher genital infection rates in patients, researchers added.

Related Summaries